These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24002275)

  • 1. Optimizing the use of pneumococcal conjugate vaccine globally.
    O'Brien KL
    JAMA; 2013 Sep; 310(9):911-3. PubMed ID: 24002275
    [No Abstract]   [Full Text] [Related]  

  • 2. The heptavalent pneumococcal conjugate vaccine immunization project by Bangkok Metropolitan in Thai infants.
    Liulak W; Thisyakorn U
    J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S13-5. PubMed ID: 21298831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the new pneumococcal conjugate vaccine in the USA.
    Baucher H
    Arch Dis Child; 2000 Nov; 83(5):396. PubMed ID: 11040145
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal polysaccharide-protein CRM197 conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule.
    Fritzell B; Fletcher MA
    Expert Rev Vaccines; 2011 Mar; 10(3):263-90. PubMed ID: 21434795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges to pneumococcal vaccine in India.
    Kanungo R
    Indian J Med Microbiol; 2013; 31(1):1-2. PubMed ID: 23508420
    [No Abstract]   [Full Text] [Related]  

  • 7. Will two doses of pneumococcal conjugate vaccine be enough?
    Russell FM; Chokephaibulkit K
    Lancet Infect Dis; 2024 May; 24(5):449-451. PubMed ID: 38310907
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization for Streptococcus pneumoniae infections in high-risk children.
    Committee On Infectious Diseases
    Pediatrics; 2014 Dec; 134(6):1230-3. PubMed ID: 25422018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.
    Spijkerman J; Veenhoven RH; Wijmenga-Monsuur AJ; Elberse KE; van Gageldonk PG; Knol MJ; de Melker HE; Sanders EA; Schouls LM; Berbers GA
    JAMA; 2013 Sep; 310(9):930-7. PubMed ID: 24002279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination against invasive pneumococcal disease in Saudi Arabia: where do we stand?
    Frayha HH; Al Mazrou YY
    Ann Saudi Med; 2005; 25(2):90-3. PubMed ID: 15977683
    [No Abstract]   [Full Text] [Related]  

  • 12. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus.
    Hadjipanayis A; Efstathiou E; Michaelidou K; Papaevangelou V
    Vaccine; 2018 Sep; 36(38):5685-5691. PubMed ID: 30115523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
    Gladstone RA; Jefferies JM; Faust SN; Clarke SC
    Expert Rev Vaccines; 2012 Aug; 11(8):889-902. PubMed ID: 23002969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present.
    Trück J; Lazarus R; Jonsdottir I; Klugman KP; Pollard AJ
    Clin Infect Dis; 2012 Dec; 55(11):1577-9; author reply 1579-81. PubMed ID: 22903769
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population.
    Verhagen LM; Rivera-Olivero IA; Hermsen M; Sisco MC; Maes M; Del Nogal B; Bogaert D; Berbers GA; Hermans PW; de Jonge MI; de Waard JH
    Eur Respir J; 2016 Nov; 48(5):1492-1496. PubMed ID: 27540017
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
    Dagan R; Givon-Lavi N; Porat N; Greenberg D
    Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serious invasive pneumococcal disease in young children: the importance of vaccination].
    Haveman LM; Geelen SP; Sanders EA; Wolfs TF
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1917-20. PubMed ID: 12404904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?
    Musher DM
    Clin Infect Dis; 2012 Jul; 55(2):265-7. PubMed ID: 22495544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.